NanoViricides Secures $6 Million in Financing to Advance Antiviral Drug Development

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral nanomedicines, has entered into a securities purchase agreement with a single healthcare institutional investor for the purchase of 3,571,429 shares of common stock at $1.68 per share in a registered direct offering. The transaction is expected to generate approximately $6 million in gross proceeds before expenses, providing essential capital for the company's ongoing development programs. In a concurrent private placement, the company will issue Series A warrants and Series B warrants to purchase up to 3,571,429 shares each, with exercise prices of $1.75 and $2.00 per share respectively, offering additional potential funding avenues for future development needs.

The financing comes at a critical juncture for NanoViricides as the company advances its lead drug candidate NV-387 toward Phase II human clinical trials. NV-387 represents a broad-spectrum antiviral drug that the company plans to develop as a treatment for multiple respiratory viral infections including RSV, COVID-19, Long COVID, and influenza, as well as MPOX/Smallpox infections. The company's other advanced drug candidate, NV-HHV-1, targets the treatment of Shingles, expanding the company's pipeline across multiple viral indications. The company's development approach leverages its nanoviricide technology platform, which is based on intellectual property, technology and proprietary know-how licensed from TheraCour Pharma, Inc.

Proceeds from this financing will be used for working capital and general corporate purposes, supporting the company's continued research and development efforts across its antiviral portfolio. The closing of the offering is expected on or about November 12, 2025, subject to customary closing conditions, with A.G.P./Alliance Global Partners acting as sole placement agent for the transaction. This funding represents a significant milestone in NanoViricides' capital strategy as it navigates the complex and capital-intensive process of drug development.

NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology, which the company holds under exclusive perpetual licenses for several drugs targeting specific viral diseases. The company's licensed fields include Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B and C viruses, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza and Asian Bird Flu Virus, Dengue viruses, and certain Coronaviruses, among others. The company maintains additional development programs against viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.

The successful completion of this $6 million financing provides NanoViricides with additional resources to advance its clinical programs while maintaining its strategic focus on developing novel antiviral therapeutics. As with any pharmaceutical development company, NanoViricides faces the inherent challenges of drug development, including the lengthy timeline and substantial capital requirements typical of the industry. The company continues to work toward advancing its pipeline while managing the uncertainties inherent in clinical development, where successful laboratory results must ultimately translate to effective and safe treatments in human trials.